Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 9, Issue 7, 2015, Pages 525-531

  Roblin, X ^a   Marotte, H ^a   Leclerc, M ^a   Del Tedesco, E ^a   Phelip, J M ^a   Peyrin Biroulet, L ^b   Paul, S ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

antibodies to infliximab; Crohn's disease; inflammatory bowel disease; Infliximab; kinetics; loss of response; ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; INFLIXIMAB; ANTIBODY; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CROHN DISEASE ACTIVITY INDEX; DISEASE DURATION; DRUG DOSE INTENSIFICATION; DRUG MONITORING; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SEX RATIO; TREATMENT FAILURE; TREATMENT RESPONSE; BLOOD; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG TOLERANCE; IMMUNOLOGY; METABOLISM; YOUNG ADULT;

ADULT; ANTIBODIES; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84963754619     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv061     Document Type: Article

References (19)

1. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7
2. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106:674-84
3. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease [IBD]: a meta-analysis. Am J Gastroenterol 2013;108:40-7
4. Paul S, Moreau AC, Del Tedesco E, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis 2014;20:1288-95
5. Steenholdt C, Al-khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2209-17
6. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108:962-71
7. Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimising infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014;109:1055-64
8. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014;63:1258-64
9. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and antiadalimumab antibodies in patients with Crohn's disease. J Gastroenterol 2014;49:100-9
10. Bortlik M, Duricova, D., Malickova, K. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease: a single cohort study. J Crohns Colitis 2012; 6:S153
11. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 2014;20:1996-2003
12. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patients serum. J Immunol Methods 2012;382:177-88
13. Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's Disease. Clin Gastroenterol Hepatol 2015;13:514-21
14. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-95
15. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444-7
16. Cornillie F, Hanauer S, Diamond R, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014;63:1721-7
17. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012;36:765-71
18. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-24
19. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015;13:522-30